A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
In the register
The register attaches this trial to Dalosirvat (SM-04554) (Biosplice Therapeutics), currently at “Phase 2/3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Biosplice Therapeutics, Inc.
- Participants (registry)
- 302
- Start
- November 2014
- Primary completion
- November 2015
- Study completion
- November 2015
- Last registry update
- October 2026
- Countries
- United States
Conditions studied: Androgenetic Alopecia
Interventions: Topical SM04554 solution, Topical SM04554 solution, Topical vehicle solution
Other trials of Dalosirvat (SM-04554)
A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.